FOSUN PHARMA
复星医药

上海復星醫藥（集團）股份有限公司
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

VOLUNTARY ANNOUNCEMENT IN RELATION TO THE 2025 H SHARE REPURCHASE PLAN AND THE 2025 A SHARE REPURCHASE PLAN

This announcement is made on a voluntary basis by Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the "**Company**").

The board of directors of the Company (the "**Board**") is pleased to announce that on 22 January 2025, in order to preserve the value of the Company, pursuant to the general mandate (the "**H Share Repurchase Mandate**") to repurchase H shares of the Company (the "**H Shares**") and the general mandate to repurchase A shares of the Company (the "**A Shares**") granted to the Board by the shareholders of the Company at the annual general meeting, the class meeting of H Shares and the class meeting of A Shares of the Company held on 26 June 2024 (the "**Date of the General Meeting**"), it has approved the implementation of a H Shares repurchase plan (the "**2025 H Share Repurchase Plan**") and an A Shares repurchase plan (the "**2025 A Share Repurchase Plan**") during the six months commencing from the date of the Board approval (i.e. 22 January 2025).

The 2025 H Share Repurchase Plan

Pursuant to the 2025 H Share Repurchase Plan, the total number of H Shares proposed to be repurchased shall not exceed 5% of the total number of H Shares (i.e. not exceeding 27,597,025 shares as at the Date of the General Meeting (i.e. 551,940,500 shares). The usage of those H Shares to be repurchased will be decided by the Company in accordance with the H Share Repurchase Mandate and factors such as market conditions, including but not limited to cancellation of the repurchased H Shares, or holding the same as treasury shares.

The 2025 A Share Repurchase Plan

Pursuant to the 2025 A Share Repurchase Plan, it is proposed that the total amount of funds for repurchasing A Shares shall not be less than RMB300 million and not more than RMB600 million (both inclusive). Any A Shares repurchased by the Company under the 2025 A Share Repurchase Plan may be used by the Company for (1) the issuance of shares for the conversion of convertible bonds, and/or (2) the implementation of the equity incentive plan and/or employee share ownership scheme in the future. If the A Shares repurchased are not transferred in accordance with the above purpose(s) within the period required by the relevant laws and regulations and regulatory requirements of the venue at which the Company's A Shares are listed, the relevant shares will be cancelled within 3 years after the announcement of the repurchase results of the 2025 A Share Repurchase Plan.

The 2025 H Share Repurchase Plan and the 2025 A Share Repurchase Plan shall be funded by self-owned funds and/or self-raised funds. The implementation period of the H Share Repurchase Plan and the A Share Repurchase Plan will be six months from the date of approval of such repurchase plan(s) by the Board (i.e. from 22 January 2025 to 21 July 2025 (both dates inclusive)). In the event that the implementation of such repurchase plan(s) has not been completed by the conclusion of the next annual general meeting of the Company, the continuation of the relevant repurchases under such repurchase plan(s) shall be subject to the approval(s) of general mandate to repurchase the relevant H Shares and/or A Shares by the general meeting as well as relevant class meetings of H Shares and A Shares (if applicable).

Shareholders and potential investors should note that any repurchase will be subject to market conditions and compliance with applicable laws and regulations, any regulatory requirements of the venue at which the Company's shares are listed as well as the rules of the articles of association of the Company. The Company makes no assurance as to the timing, quantity or price of any repurchases. Accordingly, shareholders and potential investors are reminded to exercise caution when dealing in the securities of the Company.

By Order of the Board
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Wu Yifang
Chairman

Shanghai, the PRC
22 January 2025

As at the date of this announcement, the executive directors of the Company are Mr. Wu Yifang, Mr. Wang Kexin, Ms. Guan Xiaohui and Mr. Wen Deyong; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Xu Xiaoliang, Mr. Pan Donghui and Mr. Chen Yuqing; and the independent non-executive directors of the Company are Ms. Li Ling, Mr. Tang Guliang, Mr. Wang Quandi and Mr. Yu Tze Shan Hailson.

* *For identification purposes only*